New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder Two further US patents granted Equity financing raises gross proceeds of $144 million Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) on track to report data by end of 2021…


Previous articleMindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development
Next articleRoutes of Administration in Psychedelic Drug Research